Cover Image
市場調查報告書

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e) :開發中產品分析

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 364833
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e) :開發中產品分析 T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H1 2018
出版日期: 2018年02月13日 內容資訊: 英文 74 Pages
簡介

本報告提供以T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e)概要

治療藥的開發

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):開發中的產品 - 各開發階段

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):開發中的產品 - 各治療範圍

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):開發中的產品 - 各適應症

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):企業開發中的產品

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):大學/機關開發中的產品

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e)治療藥的開發企業

  • Amgen Inc.
  • GlaxoSmithKline Plc
  • MacroGenics, Inc.
  • Tiziana Life Sciences Plc
  • Xencor, Inc.

藥物簡介

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):暫停中的計劃

T細胞表面糖蛋白CD3ε鏈 (T細胞表面抗原T3/Leu-4ε鏈或CD3e):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1292TDB

Summary

According to the recently published report 'T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H1 2018'; T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - T-Cell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. T-cell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAPand NCK2. The CD3 complex mediates signal transduction, resulting in T-cell activation and proliferation.

The report 'T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H1 2018' outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Immunology, Central Nervous System, Infectious Disease and Musculoskeletal Disorders which include indications Type 1 Diabetes (Juvenile Diabetes), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Inflammatory Bowel Disease, Multiple Myeloma (Kahler Disease), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Autoimmune Disorders, Chronic Inflammation, Crohn's Disease (Regional Enteritis), Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Hepatitis B, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Sclerosis, Nodal Marginal Zone B-Cell Lymphoma, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cirrhosis, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Solid Tumor, Splenic Marginal Zone B-Cell Lymphoma and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
  • The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics and enlists all their major and minor projects
  • The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview
    • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Celgene Corp
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline Plc
    • MacroGenics Inc
    • Meridigen Biotech Co Ltd
    • Numab Innovation AG
    • SYNIMMUNE GmbH
    • Tiziana Life Sciences Plc
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles
    • AMG-330 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVA-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibody to Target CD3E and PSMA for Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • blinatumomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Coltelizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EM-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • foralumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • otelixizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasotuxizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-6026 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-7082859 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TACSYN - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teplizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XmAb-13551 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 09, 2018: Application for Marketing Approval Submitted for Bispecific CD19-directed CD3 T Cell Engager (BiTE) Antibody Construct Blinatumomab for Relapsed or Refractory B- cell Precursor Acute Lymphoblastic Leukemia in Japan
      • Sep 06, 2017: Development of a Proprietary Oral Formulation of Foralumab, a Fully Human Anti-CD3 mAb, for use in an Upcoming Phase 2a Clinical Trial in NASH
      • Jul 28, 2017: Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
      • Jul 11, 2017: FDA Grants Full Approval for BLINCYTO (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children
      • Jun 23, 2017: European Hematology Association: The More the T-lymphocytes Differ, the More Effectively They Fight Against Leukemia
      • Jun 21, 2017: Amgen To Present Data on BLINCYTO At 22nd Congress of the European Hematology Association
      • Jun 02, 2017: City of Hope Presents Study Results of Blinatumomab at 2017 American Society of Clinical Oncology meeting
      • Mar 29, 2017: FDA Grants Priority Review For Amgen's BLINCYTO (blinatumomab) Supplemental Biologics License Application
      • Mar 29, 2017: Journal Of Clinical Oncology Publishes Data On BLINCYTO (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
      • Mar 14, 2017: Tiziana Life Sciences Appoints Dr. Arun Sanyal to its Scientific Advisory Board
      • Mar 01, 2017: BLINCYTO (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
      • Feb 14, 2017: Amgen Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
      • Nov 30, 2016: Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia At ASH 2016
      • Nov 18, 2016: New Publication: Partial Exhaustion of CD8 T Cells in Responders to Anti-CD3 Treatment in New-Onset Type 1 Diabetes
      • Nov 16, 2016: Tiziana Life Sciences Announces New Data with Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Amgen Inc, H1 2018
  • Pipeline by Celgene Corp, H1 2018
  • Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
  • Pipeline by GlaxoSmithKline Plc, H1 2018
  • Pipeline by MacroGenics Inc, H1 2018
  • Pipeline by Meridigen Biotech Co Ltd, H1 2018
  • Pipeline by Numab Innovation AG, H1 2018
  • Pipeline by SYNIMMUNE GmbH, H1 2018
  • Pipeline by Tiziana Life Sciences Plc, H1 2018
  • Dormant Projects, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top